Trial Profile
A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs CPC 551 (Primary)
- Indications Age-related macular degeneration; Dry macular degeneration
- Focus Therapeutic Use
- Sponsors Othera Pharmaceuticals
- 23 May 2014 New trial record